GSK Invests $10.6 Billion in Lung Cancer Research and Development

Pharmaceutical giant GSK has committed $10.6 billion to a significant investment in lung cancer research and development, signaling a major strategic bet in the oncology sector.

9 Jun, 16:57 — 9 Jun, 16:57

Post Share

Sources

Showing 1 of 2 sources

FTVery High2d ago

GSK’s $10.6bn cancer deal will lead to more

Making additional moves would be in keeping with pharma group’s strategy of building its pipeline as fast as possible

Read full article →

Coverage Timeline

First report: Yahoo · 9 Jun, 15:29|Full coverage: 2 · 1h|Window: 1h

Left-leaningCenterRight-leaning

Yahoo9 Jun, 15:29First to report

GSK Just Dropped $10.6 Billion on a Lung Cancer Bet

1h later

FT9 Jun, 16:57Latest update

PERSPECTA

PERSPECTA

GSK Invests $10.6 Billion in Lung Cancer Research and Development

Sources

GSK’s $10.6bn cancer deal will lead to more

Coverage Timeline

GSK Just Dropped $10.6 Billion on a Lung Cancer Bet

GSK’s $10.6bn cancer deal will lead to more

Related Stories

Amazon's First Customer Receipt Goes Viral, Bezos and Musk React

Nigeria Explores Diversified Energy Mix to Address Electricity Shortages

Nigerian Senate Invalidates Arrest Warrant for Former NNPC MD Mele Kyari

SK Hynix Explores Broader AI Adoption for Workplace Innovation

PERSPECTA